DK3481859T3 - Opløselig fibroblastvækstfaktorreceptor 3 (SFGFR3)-polypeptider og anvendelser deraf - Google Patents
Opløselig fibroblastvækstfaktorreceptor 3 (SFGFR3)-polypeptider og anvendelser deraf Download PDFInfo
- Publication number
- DK3481859T3 DK3481859T3 DK17742195.5T DK17742195T DK3481859T3 DK 3481859 T3 DK3481859 T3 DK 3481859T3 DK 17742195 T DK17742195 T DK 17742195T DK 3481859 T3 DK3481859 T3 DK 3481859T3
- Authority
- DK
- Denmark
- Prior art keywords
- sfgfr3
- polypeptides
- growth factor
- factor receptor
- fibroblast growth
- Prior art date
Links
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359607P | 2016-07-07 | 2016-07-07 | |
| US201762467478P | 2017-03-06 | 2017-03-06 | |
| PCT/EP2017/067119 WO2018007597A1 (en) | 2016-07-07 | 2017-07-07 | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3481859T3 true DK3481859T3 (da) | 2022-04-25 |
Family
ID=59381265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17742195.5T DK3481859T3 (da) | 2016-07-07 | 2017-07-07 | Opløselig fibroblastvækstfaktorreceptor 3 (SFGFR3)-polypeptider og anvendelser deraf |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294289B2 (https=) |
| EP (2) | EP3481859B1 (https=) |
| JP (2) | JP7046903B2 (https=) |
| KR (2) | KR20220122762A (https=) |
| CN (1) | CN109715658B (https=) |
| AU (2) | AU2017294551B2 (https=) |
| BR (1) | BR112019000257A2 (https=) |
| CA (1) | CA3029877C (https=) |
| DK (1) | DK3481859T3 (https=) |
| ES (1) | ES2912559T3 (https=) |
| HU (1) | HUE058734T2 (https=) |
| IL (1) | IL264030A (https=) |
| MX (1) | MX2018016257A (https=) |
| PL (1) | PL3481859T3 (https=) |
| PT (1) | PT3481859T (https=) |
| RU (1) | RU2751483C2 (https=) |
| SG (1) | SG11201900074WA (https=) |
| SI (1) | SI3481859T1 (https=) |
| WO (1) | WO2018007597A1 (https=) |
| ZA (1) | ZA201900507B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013373679A1 (en) | 2013-01-16 | 2015-08-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PT3481859T (pt) | 2016-07-07 | 2022-05-23 | Pfizer | Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos |
| JP7335247B2 (ja) * | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
| US12390510B2 (en) | 2019-05-29 | 2025-08-19 | Massachusetts Eye And Ear Infirmary | Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2) |
| US11625937B2 (en) * | 2020-04-06 | 2023-04-11 | Toyota Motor Engineering & Manufacturing North America, Inc. | Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| DE69619526T2 (de) | 1995-06-12 | 2002-10-31 | Yeda Research And Development Co., Ltd. | Fgf9 als spezifischer ligand für fgfr3 |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| CA2432257A1 (en) | 2000-12-18 | 2002-06-27 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| CA2558758C (en) | 2004-02-24 | 2015-06-23 | Allergan, Inc. | Botulinum toxin screening assays |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| EP2046384A4 (en) | 2006-06-15 | 2009-12-02 | Fibron Ltd | ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME |
| US8962556B2 (en) | 2006-09-28 | 2015-02-24 | Prochon Biotech Ltd. | FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| CN102171343B (zh) * | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| TWI507205B (zh) | 2009-03-25 | 2015-11-11 | Genentech Inc | 抗ｆｇｆｒ３抗體及使用方法 |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| BR112012016992A2 (pt) | 2010-01-14 | 2019-09-24 | Univ Yale | "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena". |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| AU2012328880B2 (en) | 2011-10-24 | 2017-02-23 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| CN104797936B (zh) | 2012-07-24 | 2017-11-24 | 纽约市哥伦比亚大学理事会 | 融合蛋白及其方法 |
| CA2878183A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| CA2890346A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| AU2013373679A1 (en) | 2013-01-16 | 2015-08-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
| US20180148494A1 (en) | 2015-01-07 | 2018-05-31 | TheAchon | Soluble fgfr3 decoys for treating skeletal growth disorders |
| PT3481859T (pt) | 2016-07-07 | 2022-05-23 | Pfizer | Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos |
| JP7335247B2 (ja) | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
-
2017
- 2017-07-07 PT PT177421955T patent/PT3481859T/pt unknown
- 2017-07-07 CN CN201780049433.8A patent/CN109715658B/zh not_active Expired - Fee Related
- 2017-07-07 MX MX2018016257A patent/MX2018016257A/es unknown
- 2017-07-07 EP EP17742195.5A patent/EP3481859B1/en active Active
- 2017-07-07 HU HUE17742195A patent/HUE058734T2/hu unknown
- 2017-07-07 PL PL17742195T patent/PL3481859T3/pl unknown
- 2017-07-07 SI SI201731158T patent/SI3481859T1/sl unknown
- 2017-07-07 DK DK17742195.5T patent/DK3481859T3/da active
- 2017-07-07 AU AU2017294551A patent/AU2017294551B2/en not_active Ceased
- 2017-07-07 BR BR112019000257A patent/BR112019000257A2/pt not_active IP Right Cessation
- 2017-07-07 CA CA3029877A patent/CA3029877C/en active Active
- 2017-07-07 JP JP2019500261A patent/JP7046903B2/ja not_active Expired - Fee Related
- 2017-07-07 RU RU2019100381A patent/RU2751483C2/ru active
- 2017-07-07 EP EP22167483.1A patent/EP4122955A1/en not_active Withdrawn
- 2017-07-07 ES ES17742195T patent/ES2912559T3/es active Active
- 2017-07-07 KR KR1020227027503A patent/KR20220122762A/ko not_active Ceased
- 2017-07-07 SG SG11201900074WA patent/SG11201900074WA/en unknown
- 2017-07-07 WO PCT/EP2017/067119 patent/WO2018007597A1/en not_active Ceased
- 2017-07-07 KR KR1020197002602A patent/KR102432192B1/ko active Active
-
2018
- 2018-04-02 US US15/943,436 patent/US10294289B2/en active Active
- 2018-12-30 IL IL264030A patent/IL264030A/en unknown
-
2019
- 2019-01-24 ZA ZA2019/00507A patent/ZA201900507B/en unknown
- 2019-05-20 US US16/417,174 patent/US11021528B2/en not_active Expired - Fee Related
-
2021
- 2021-04-20 US US17/234,841 patent/US11697678B2/en active Active
-
2022
- 2022-03-23 JP JP2022046573A patent/JP7348980B2/ja active Active
- 2022-05-02 AU AU2022202906A patent/AU2022202906A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3481859T3 (da) | Opløselig fibroblastvækstfaktorreceptor 3 (SFGFR3)-polypeptider og anvendelser deraf | |
| DK3784283T3 (da) | Cannabidiopræparater og anvendelser deraf | |
| PT3494134T (pt) | Polipéptidos artificiais e sua utilização | |
| DK3706762T3 (da) | N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil | |
| DK3849614T3 (da) | Interleukin-2-polypeptidkonjugater og anvendelser deraf | |
| DK3596053T3 (da) | Farnesoid-x-receptoragonister og anvendelser deraf | |
| DK3655401T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3625263T3 (da) | Anti-galectin- 9-antistoffer og anvendelser deraf | |
| DK3497094T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3555064T3 (da) | GLP-1 receptoragonister og anvendelser deraf | |
| DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3710067T3 (da) | D-domæne indeholdende polypeptider og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3368554T3 (da) | Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme | |
| IL280922A (en) | Anti-her2 polypeptides and methods of use thereof | |
| DK3596125T3 (da) | Anti-PAR2-antistoffer og anvendelser deraf | |
| IL280808A (en) | OX40-binding polypeptides and their uses | |
| DK3692015T3 (da) | Hidtil ukendte glutaminantagonister og anvendelser deraf | |
| DK3145945T3 (da) | Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf | |
| DK3514153T3 (da) | Pyrimidinforbindelse og farmaceutisk anvendelse deraf | |
| DK3743106T3 (da) | Influenzavirusvacciner og anvendelser deraf | |
| DK3678687T3 (da) | Mutant fgf-21 peptidkonjugater og anvendelser deraf | |
| DK3360895T3 (da) | Præparat omfattende faktor-viii og von-willebrand-faktor-peptider | |
| DK3426680T3 (da) | Aktivin type 2 receptor bindende proteiner og anvendelser deraf |